Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls
Martina Calusic, Robert Marcec, Lea Luksa, Ivan Jurkovic, Natasa Kovac, Slobodan Mihaljevic, MD Robert Likic
British Journal of Clinical Pharmacology, doi:10.1111/bcp.15126
Background: Fluvoxamine, an SSRI and sigma-1 receptor agonist, has so far shown promise in the prevention of COVID-19 progression as an early treatment option in 3 conducted trials. The aim of this study was to evaluate the safety and efficacy of fluvoxamine in COVID-19 patients if administered later in the disease's course. Methods: The study was designed as an open label, prospective cohort trial with matched controls. In April and May 2021, 51 ICU COVID-19 patients hospitalised in the
References
Anderson, Fluvoxamine , melatonin and COVID
Asakura, Koyama, Hosokai, Kawano, Kajii, Post-Marketing Surveillance of Fluvoxamine Maleate Used Long-Term in Patients with Social Anxiety Disorder in Japan, Drugs -Real World Outcomes,
doi:10.1007/s40801-014-0005-2
Buchberger, Wagner, Fluvoxamine: Safety profile in extensive post-marketing surveillance, Pharmacopsychiatry,
doi:10.1055/s-2002-31522
Carpinteiro, Edwards, Hoffmann, Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells, Cell Reports Med,
doi:10.1016/j.xcrm.2020.100142
Elbahlawan, Bissler, Morrison, Continuous Renal Replacement Therapy: A Review of Use and Application in Pediatric Hematopoietic Stem Cell Transplant Recipients, Front Oncol,
doi:10.3389/fonc.2021.632263
Esfahani, Rafiee, Javanmard, Evaluation of the Effect of Antidepressant Drug, Fluvoxamine, on Cyclooxygenase-2 Protein Expression in Lipopolysaccharide-stimulated Macrophages, Adv Biomed Res,
doi:10.4103/abr.abr_141_18
Hashimoto, Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor, Eur Arch Psychiatry Clin Neurosci,
doi:10.1007/s00406-020-01231-x
Hassanipour, Arab-Zozani, Amani, Heidarzad, Fathalipour et al., The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials, Sci Rep,
doi:10.1038/s41598-021-90551-6
Hinks, Cureton, Knight, Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial, Lancet Respir Med,
doi:10.1016/s2213-2600(21)00263-0
Hoertel, Sánchez-Rico, Cougoule, Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms, Mol Psychiatry,
doi:10.1038/s41380-021-01254-3
Homolak, Kodvanj, Widely available lysosome targeting agents should be considered as potential therapy for COVID-19
Hägg, Spigset, Dahlqvist, Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers, Br J Clin Pharmacol,
doi:10.1046/j.1365-2125.2001.01328
Lenze, Mattar, Zorumski, Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients with Symptomatic COVID-19: A Randomized Clinical Trial, JAMA -J Am Med Assoc,
doi:10.1001/jama.2020.22760
Marčec, Likić, Could fluvoxamine keep COVID-19 patients out of hospitals and intensive care units?, Croat Med J,
doi:10.3325/CMJ.2021.62.95
Moiseev, Brovko, Tao, Bulanov, Akulkina et al., Sex differences in mortality in the intensive care unit patients with severe COVID-19, J Infect,
doi:10.1016/j.jinf.2020.09.031
Rosen, Seki, Fernández-Castañeda, Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis, Sci Transl Med,
doi:10.1126/scitranslmed.aau5266
Schloer, Brunotte, Goretzko, Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine, Emerg Microbes Infect,
doi:10.1080/22221751.2020.1829082
Seftel, Boulware, Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19, Open Forum Infect Dis,
doi:10.1093/ofid/ofab050
Servillo, Vargas, Pastore, Immunomodulatory effect of continuous venovenous hemofiltration during sepsis: Preliminary data, Biomed Res Int,
doi:10.1155/2013/108951
Sukhatme, Reiersen, Vayttaden, Sukhatme, Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19, Front Pharmacol,
doi:10.3389/fphar.2021.652688
Who, COVID-19 Weekly Epidemiological Update 55